Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
“Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
A Japanese version of compassionate use is expected to place a huge burden on drug makers as they will be urged to conduct additional unscheduled trials for a humanitarian cause, said the regulatory affairs chief of the Japan Pharmaceutical Manufacturers…
To read the full story
Related Article
- “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Introduction of GDP Guideline Would Require Investment in Distribution Systems: JPMA Quality Chief
August 19, 2015
- Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief
August 14, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- “All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
August 3, 2015
- Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
- Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs
December 22, 2014
- Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
- Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center
July 23, 2013
ORGANIZATION
- BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026
- Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
- FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
- FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…